A Phase 1/1B Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination with Irinotecan in Subjects with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2012
At a glance
- Drugs Iniparib; Irinotecan
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- 21 Jun 2012 Additional trial identifier (20060101) identified as reported by ClinicalTrials.gov record.
- 14 May 2012 Actual patient number is 59 according to ClinicalTrials.gov.
- 26 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.